Literature DB >> 31648333

Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice.

Weiqing Jing1, Juan Chen1, Yuanhua Cai1,2, Yingyu Chen1,2, Jocelyn A Schroeder1,2, Bryon D Johnson2,3,4,5,6, Weiguo Cui1,4, Qizhen Shi1,2,5,6.   

Abstract

The development of neutralizing anti-FVIII antibodies (inhibitors) is a major complication of FVIII protein replacement therapy in patients with hemophilia A (HA). Although multiple lines of evidence indicate that the immune response against FVIII is CD4 T-cell-dependent and many FVIII-derived CD4 epitopes have already been discovered, the role of T follicular helper (TFH) cells in FVIII inhibitor development is unknown. TFH cells, a newly identified subset of CD4 T cells, are characterized by expression of the B-cell follicle-homing receptor CXCR5 and PD-1. In this study, we show for the first time that IV FVIII immunization induces activation and accumulation and/or expansion of PD-1+CXCR5+ TFH cells in the spleen of FVIII-deficient (FVIIInull) mice. FVIII inhibitor-producing mice showed increased germinal center (GC) formation and increased GC TFH cells in response to FVIII immunization. Emergence of TFH cells correlated with titers of anti-FVIII inhibitors. Rechallenge with FVIII antigen elicited recall responses of TFH cells. In vitro FVIII restimulation resulted in antigen-specific proliferation of splenic CD4+ T cells from FVIII-primed FVIIInull mice, and the proliferating cells expressed the TFH hallmark transcription factor BCL6. CXCR5+/+ TFH-cell-specific deletion impaired anti-FVIII inhibitor production, confirming the essential role of CXCR5+/+ TFH cells for the generation of FVIII-neutralizing antibodies. Together, our results demonstrate that the induction of activated TFH cells in FVIIInull mice is critical for FVIII inhibitor development, suggesting that inhibition of FVIII-specific TFH-cell activation may be a promising strategy for preventing anti-FVIII inhibitor formation in patients with HA.
© 2019 by The American Society of Hematology.

Entities:  

Year:  2019        PMID: 31648333      PMCID: PMC6849959          DOI: 10.1182/bloodadvances.2019000650

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  56 in total

Review 1.  T follicular helper cell differentiation, function, and roles in disease.

Authors:  Shane Crotty
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

Review 2.  CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm.

Authors:  Kiyoshi Hirahara; Toshinori Nakayama
Journal:  Int Immunol       Date:  2016-02-12       Impact factor: 4.823

3.  Germinal center T follicular helper cell IL-4 production is dependent on signaling lymphocytic activation molecule receptor (CD150).

Authors:  Isharat Yusuf; Robin Kageyama; Laurel Monticelli; Robert J Johnston; Daniel Ditoro; Kyle Hansen; Burton Barnett; Shane Crotty
Journal:  J Immunol       Date:  2010-06-04       Impact factor: 5.422

Review 4.  Signals that drive T follicular helper cell formation.

Authors:  Louise M C Webb; Michelle A Linterman
Journal:  Immunology       Date:  2017-07-17       Impact factor: 7.397

5.  HLA-DR-presented peptide repertoires derived from human monocyte-derived dendritic cells pulsed with blood coagulation factor VIII.

Authors:  Simon D van Haren; Eszter Herczenik; Anja ten Brinke; Koen Mertens; Jan Voorberg; Alexander B Meijer
Journal:  Mol Cell Proteomics       Date:  2011-04-05       Impact factor: 5.911

Review 6.  T cells as a therapeutic target in SLE.

Authors:  D Comte; M P Karampetsou; G C Tsokos
Journal:  Lupus       Date:  2015-04       Impact factor: 2.911

7.  The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.

Authors:  Q Shi; J A Schroeder; E L Kuether; R R Montgomery
Journal:  J Thromb Haemost       Date:  2015-06-11       Impact factor: 5.824

8.  Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A.

Authors:  L Bi; A M Lawler; S E Antonarakis; K A High; J D Gearhart; H H Kazazian
Journal:  Nat Genet       Date:  1995-05       Impact factor: 38.330

9.  Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response.

Authors:  Braden Waters; Mohammad Qadura; Erin Burnett; Rouzbeh Chegeni; Andrea Labelle; Patrick Thompson; Christine Hough; David Lillicrap
Journal:  Blood       Date:  2008-09-24       Impact factor: 22.113

Review 10.  Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A.

Authors:  Sébastien Lacroix-Desmazes; Ana-Maria Navarrete; Sébastien André; Jagadeesh Bayry; Srinivas V Kaveri; Suryasarathi Dasgupta
Journal:  Blood       Date:  2008-05-09       Impact factor: 22.113

View more
  13 in total

Review 1.  Recent advances in lentiviral vectors for gene therapy.

Authors:  Xiaoyu Wang; Cuicui Ma; Roberto Rodríguez Labrada; Zhou Qin; Ting Xu; Zhiyao He; Yuquan Wei
Journal:  Sci China Life Sci       Date:  2021-07-14       Impact factor: 6.038

2.  Association of Platelet Desialylation and Circulating Follicular Helper T Cells in Patients With Thrombocytopenia.

Authors:  Yuwen Chen; Liping Luo; Yongzhi Zheng; Qiaoyun Zheng; Na Zhang; Donghui Gan; Shimuye Kalayu Yirga; Zhenxing Lin; Qizhen Shi; Lin Fu; Jianda Hu; Yingyu Chen
Journal:  Front Immunol       Date:  2022-04-01       Impact factor: 8.786

3.  Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway.

Authors:  Seema R Patel; Taran S Lundgren; Wallace Hunter Baldwin; Courtney Cox; Ernest T Parker; John F Healey; Ryan P Jajosky; Patricia E Zerra; Cassandra D Josephson; Christopher B Doering; Sean R Stowell; Shannon L Meeks
Journal:  Front Immunol       Date:  2022-05-11       Impact factor: 8.786

4.  B cell-activating factor modulates the factor VIII immune response in hemophilia A.

Authors:  Bhavya S Doshi; Jyoti Rana; Giancarlo Castaman; Mostafa A Shaheen; Radoslaw Kaczmarek; John Ss Butterfield; Shannon L Meeks; Cindy Leissinger; Moanaro Biswas; Valder R Arruda
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

5.  Unexpected enhancement of FVIII immunogenicity by endothelial expression in lentivirus-transduced and transgenic mice.

Authors:  Qizhen Shi; Christopher V Carman; Yingyu Chen; Peter T Sage; Feng Xue; Xin M Liang; Gary E Gilbert
Journal:  Blood Adv       Date:  2020-05-26

6.  Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include Up-Regulated Innate Immune Modulators.

Authors:  Ahmad Faisal Karim; Anthony R Soltis; Gauthaman Sukumar; Christoph Königs; Nadia P Ewing; Clifton L Dalgard; Matthew D Wilkerson; Kathleen P Pratt
Journal:  Front Immunol       Date:  2020-06-12       Impact factor: 7.561

Review 7.  Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A.

Authors:  Yuanhua Cai; Qizhen Shi
Journal:  Front Immunol       Date:  2020-06-12       Impact factor: 7.561

8.  Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation.

Authors:  Patricia E Zerra; Connie M Arthur; Satheesh Chonat; Cheryl L Maier; Amanda Mener; Sooncheon Shin; Jerry William L Allen; W Hunter Baldwin; Courtney Cox; Hans Verkerke; Ryan P Jajosky; Christopher A Tormey; Shannon L Meeks; Sean R Stowell
Journal:  Front Immunol       Date:  2020-06-09       Impact factor: 7.561

Review 9.  Tolerating Factor VIII: Recent Progress.

Authors:  Sebastien Lacroix-Desmazes; Jan Voorberg; David Lillicrap; David W Scott; Kathleen P Pratt
Journal:  Front Immunol       Date:  2020-01-10       Impact factor: 7.561

Review 10.  Escape or Fight: Inhibitors in Hemophilia A.

Authors:  Simone Merlin; Antonia Follenzi
Journal:  Front Immunol       Date:  2020-03-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.